Recurrent and Metastatic Head and Neck Cancers

Publication Date: December 15, 2022

Key Points

Key Points

  • Head and neck cancers frequently arise from the oral cavity, oropharynx, larynx, hypopharynx, or nasopharynx, and more rarely from salivary glands or paranasal sinuses.
  • Immune-checkpoint inhibitors (ICIs) are now approved as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), with or without chemotherapy.
  • The guideline provides recommendations regarding immunotherapy and biomarker testing for this diverse and complex group of diseases.

Treatment

...eatmen...

...1.1Programmed death-ligand 1 (PD-L1) immunohistoch...


...1.2PD-L1 combined positive score (CP...


...ecommendation 1.3Tumor mutational burden (TMB) t...


...mmendation 1.4TMB ≥10 should be interpret...


...ndation 2.1Pembrolizumab monotherapy...


...on 2.2Pembrolizumab, platinum, and 5-FU may be off...


...3.1Pembrolizumab or nivolumab should be offere...


....1Toripalimab, camrelizumab or tisleli...


Recommendation 4.2Programmed cell death...


...on 5.1For patients with oligometastati...


...6.1Pembrolizumab may be offered to patient...


...mendation 6.2Pembrolizumab may be offered to...


...Biomarkers and Recommendations by PD-L1 Status...


...2. Recommendations by Subtype...